Dravet Syndrome Managing Refractory Seizures Across the Lifespan

In “Dravet Syndrome Managing Refractory Seizures Across the Lifespan,” our panel explores the ongoing challenges of treating refractory seizures in patients with Dravet syndrome despite significant advances in available therapies. Expert faculty discuss why many patients continue to experience persistent seizure burden even after receiving guideline-recommended treatments and examine how treatment strategies must be individualized based on age, seizure type, disease stage, and therapeutic goals.

The discussion highlights the complexities of treatment sequencing when initial therapies fail to achieve adequate seizure control. Panelists review how management approaches differ between pediatric and adult populations, noting that many adult patients have already undergone multiple treatment trials before arriving at specialized epilepsy centers. Faculty describe how evolving disease manifestations across the lifespan can influence treatment priorities, with seizures remaining a major concern in childhood while behavioral, developmental, and caregiving challenges often become increasingly prominent in adulthood.

Expert faculty also discuss practical considerations when selecting additional therapies, including revisiting previously unsuccessful treatments, evaluating seizure-specific treatment goals, and considering nonpharmacologic interventions such as vagus nerve stimulation. The panel emphasizes that treatment decisions should be driven not only by overall seizure frequency but also by the predominant seizure types affecting an individual patient, including convulsive seizures, status epilepticus, and absence seizures.

Throughout the conversation, the panel underscores the importance of personalized care in Dravet syndrome and reflects on how improvements in currently available therapies have altered the disease trajectory for many patients. Faculty also discuss the growing role of clinical trial participation for patients who continue to experience refractory disease despite standard treatment approaches.

Our next episode, “Dravet Syndrome Treatment Monitoring and Goals for Long-Term Management,” panelists will review key monitoring requirements and treatment considerations associated with currently available therapies for Dravet syndrome. The discussion highlights the importance of balancing seizure control, treatment tolerability, and long-term quality-of-life goals through individualized care and shared decision-making.